Shpilberg, Ofer

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 1,899

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

Cohen, Y. C., Zada, M., Wang, S.-Y., Bornstein, C., David, E., Moshe, A., Li, B., Shlomi-Loubaton, S., Gatt, M. E., Gur, C., et al. (2021) · Nature Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 235

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase

Shpilberg, O., & Jackisch, C. (2013) · British Journal of Cancer

Monoclonal and Polyclonal Antibodies ResearchLymphoma Diagnosis and Treatment

Cited by 138

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 48